Shanghai Creation Investment
VC Fund
Shanghai, China
Shanghai Creation Investment is a VC fund in Shanghai focused on Medical and Manufacturing. Shanghai Creation Investment (SCI), founded in 2006, is an international venture capital firm and investment bank focused on high tech and healthcare technology. Based in Shanghai, SCI has investments in Asia, the Middle East, and the United States. SCI devoted years of efforts forming a complete eco-system for value creation for investors. Overthe last 10 years, SCI has successfully assisted more than 50 US/Israel/Chinese firms in private placement, M&A, or public offering. Raised a total amount of more than S1.25$ billion in private placement. SCI‘s investment portfolio includes 11 international star-ups and 15 Chinese companies by mid of 2017 in healthcare and hi-tech. 5 of the 25 investments are listed in the public stock market in China and USA by today.In the healthcare domain, SCI works with a large network of more than 100 hospitals and 300+ doctors in China, the Middle East, and North America, in due diligence and clinical trials for SCI’s portfolio companies. The network also contributes significant help to industry researches.SCI was awarded “Top 10 Venture Capital Firms of the Year 2016” by Private Equity Association of Shanghai, which is the largest and most important VC organization in Shanghai , with more than 330 major PE/VC firms as members.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $40M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Shanghai Creation Investment invests in
Stages Shanghai Creation Investment invests in
Countries Shanghai Creation Investment invests in
Round sizes
Round size
- Series B
- $15M–$94M
Investment Focus
Industry
- Medical 5 (36%)
- Manufacturing 5 (36%)
- Health Care 4 (29%)
- Biotechnology 3 (21%)
- Medical Device 3 (21%)
Country
- China 8 (57%)
- Israel 2 (14%)
- Canada 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Celregen Therapeutics is a pharmaceutical business that focuses on the development of novel medications in the domains of cell therapy and regenerative medicine. | $13.8M / Angel / Mar 18, 2025 | ||
| Celregen Therapeutics is a pharmaceutical business that focuses on the development of novel medications in the domains of cell therapy and regenerative medicine. | Seed / Sep 14, 2024 | ||
| Meio Medical is a developer of automatic cardiac navigation technology. It has independently developed the magnetic navigation stereotactic therapy technology, and the "MEIO magnetic navigation" stereo positioning and precise ablation system. The system consists of a magnetic navigation host, three-dimensional mapping ablation, andflexible magnetic It is composed of catheter and magnetic navigation workstation. Recently completed the Pre-A+ round of financing. This round of financing was led by Zhenghong Fund, and the old shareholder Shun'an Capital and others followed up. | Series A / Feb 28, 2023 | ||
| Shende Medical is a non-invasive medical equipment developer. It adopts a new generation of MRI-guided phased focused ultrasound technology to provide users with a new non-invasive breast adenoma ultrasound diagnosis and treatment integrated system, and a new non-invasive bone tumor advanced pain relief ultrasound Therapeutic instrument and otherproducts are used to treat diseases such as Parkinson's and brain tumors. | $15.7M / Series C / Dec 14, 2021 | ||
| Shende Medical is a non-invasive medical equipment developer. It adopts a new generation of MRI-guided phased focused ultrasound technology to provide users with a new non-invasive breast adenoma ultrasound diagnosis and treatment integrated system, and a new non-invasive bone tumor advanced pain relief ultrasound Therapeutic instrument and otherproducts are used to treat diseases such as Parkinson's and brain tumors. | $15.4M / Series B / Jul 06, 2021 | ||
| Reprobiotech is a developer of reproductive medicine technology. The company develops a platform for assisted reproductive medicine products, cutting-edge laboratories, and international standardization of GMP/ISO clean workshop, committing to promoting human health. | Series A / Jul 01, 2021 | ||
| Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million. | $93.8M / Series B / Jun 04, 2021 | ||
| Shenda Endoscope develops and manufactures medical rigid endoscopes that use French optical materials and optical fiber to ensure the performance and quality of endoscopes. | $19.9M / Series B / Jan 01, 2021 | ||
| Cygnus Biosciences (Beijing) Co., Ltd. is a high-tech company specializing in R & D and industrialization of gene sequencing platform and committed to clinical medicine screening and diagnosis. | $19.6M / Series B / Nov 14, 2017 | ||
| Zhihong Logistics provides logistics transportation services and other value-added services such as vehicle collection, trailer rental, and vehicle management services. The company helps customers to obtain efficient transportation services and high-quality delivery services.Zhihong Logistics was founded in 2003 and is headquartered in Guangzhou,Guangdong. | $29.5M / Series B / Nov 08, 2016 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shanghai Creation Investment invest in?
Shanghai Creation Investment invests primarily in Medical, Manufacturing and Health Care startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shanghai Creation Investment's check size?
Shanghai Creation Investment typically joins rounds of $15M–$94M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shanghai Creation Investment participates in.
When did Shanghai Creation Investment last invest?
The most recent investment recorded for Shanghai Creation Investment closed in Mar 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
